Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:IBIONYSE:TRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.81-4.7%$0.00$1.02▼$23.60$6.30M-3.513.04 million shs28,054 shsTRXTRX Gold$0.45-0.6%$0.39$0.31▼$0.60$125.51M0.65342,042 shs32,809 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio-1.05%+0.53%+50.00%+188,999,900.00%+188,999,900.00%TRXTRX Gold-0.02%+1.34%+21.97%+32.19%-15.66%Wall Street Legend Issues New NVDA Warning (Ad)Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBIOiBioN/AN/AN/AN/AN/AN/AN/AN/ATRXTRX Gold3.3593 of 5 stars3.50.00.00.03.20.03.1Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBioN/AN/AN/AN/ATRXTRX Gold3.00Buy$1.58250.00% UpsideCurrent Analyst RatingsLatest LCT, REDX, TRX, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024TRXTRX GoldAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $1.754/16/2024TRXTRX GoldHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.30 ➝ $1.40(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$2.38M2.65N/AN/A$15.15 per share0.12TRXTRX Gold$38.32M3.28$0.01 per share34.70$0.23 per share1.96Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/ATRXTRX Gold$2.25M$0.0145.055.63N/A0.70%-1.66%-1.18%N/ALatest LCT, REDX, TRX, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/12/2024Q2 2024TRXTRX GoldN/A$0.01+$0.01N/A$9.40 million$7.98 million 2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/ATRXTRX GoldN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBio0.040.910.91TRXTRX GoldN/A0.930.59OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%TRXTRX Gold1.06%Insider OwnershipCompanyInsider OwnershipIBIOiBio1.12%TRXTRX Gold2.25%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio263.48 million3.45 millionN/ATRXTRX Gold130278.92 million272.64 millionOptionableLCT, REDX, TRX, and IBIO HeadlinesSourceHeadlineTRX Gold (NYSE:TRX) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 25 at 2:20 AMShaquille O’Neal’s Armored Truck: A Unique Ridemsn.com - April 24 at 5:26 PMElectric Ford F-150 goes on sale in Australia – for $250,000goldcoastbulletin.com.au - April 23 at 11:24 AMFY2024 EPS Estimates for TRX Gold Co. Increased by Roth Capital (NYSE:TRX)americanbankingnews.com - April 20 at 2:42 AMEquities Analysts Offer Predictions for TRX Gold Co.'s FY2024 Earnings (NYSE:TRX)marketbeat.com - April 19 at 8:50 AMRoth Capital Equities Analysts Lift Earnings Estimates for TRX Gold Co. (NYSE:TRX)americanbankingnews.com - April 19 at 3:02 AMRoth Capital Weighs in on TRX Gold Co.'s FY2025 Earnings (NYSE:TRX)marketbeat.com - April 18 at 6:48 AMIs TRX Gold Corporation's (TSE:TRX) Recent Stock Performance Influenced By Its Fundamentals In Any Way?finance.yahoo.com - April 17 at 7:27 PMRoth MKM Keeps Their Buy Rating on Tanzanian Royalty Exploration (TRX)markets.businessinsider.com - April 17 at 2:27 PMTRX Gold (NYSE:TRX) Price Target Increased to $1.75 by Analysts at Alliance Global Partnersamericanbankingnews.com - April 17 at 4:36 AMTRX Gold (NYSE:TRX) Price Target Increased to $1.40 by Analysts at HC Wainwrightamericanbankingnews.com - April 17 at 3:48 AMTRX Gold (NYSE:TRX) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - April 17 at 2:14 AMBuy Rating Affirmed for Tanzanian Royalty Exploration Amid Strong Financials and Operational Advancementsmarkets.businessinsider.com - April 16 at 2:03 PMTRX Gold (NYSE:TRX) PT Raised to $1.75 at Alliance Global Partnersmarketbeat.com - April 16 at 1:28 PMTRX Gold nears completion of plant expansion at Buckreef gold projectproactiveinvestors.com - April 15 at 8:42 AMTRX Gold Corporation: TRX Gold Expects Significant Growth with Plant Expansion Nearing Completionfinanznachrichten.de - April 15 at 7:59 AMTRX Gold (NYSE:TRX) Issues Earnings Resultsamericanbankingnews.com - April 15 at 7:08 AMTRX Gold Expects Significant Growth with Plant Expansion Nearing Completionglobenewswire.com - April 15 at 6:30 AMCrypto Whale Incoming: Tron (TRX) And Litecoin (LTC) Exceed Expectations, Whilst Scorpion Casino (SCORP) Nears Its Official Launchoutlookindia.com - April 13 at 7:45 AMTRX Stock Earnings: TRX Gold Misses Revenue for Q2 2024markets.businessinsider.com - April 12 at 11:24 PMBlockDAG Presale Triumph: Eyeing $10 Value With 20,000x ROI Amidst TRON’s Decline And Upcoming Bitcoin Halvingfinbold.com - April 12 at 8:21 AMTRON Sees Whale Outflows; Bonk Aims For New ATH; NuggetRush Becomes Retail Favoritefinbold.com - April 10 at 8:42 AMNuggetRush’s Presale Sparks Interest Over WIF and TRON Predictable Playsmsn.com - April 7 at 1:09 PMTRX Gold Reports 2023 Annual Meeting Voting Resultsglobenewswire.com - April 5 at 4:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsiBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.TRX GoldNYSE:TRXTRX Gold Corporation engages in the exploration, development, and production of mineral property interests in the United Republic of Tanzania. The company primarily explores for gold deposits. It holds interests in the Buckreef gold project that comprises a single Special Mining License covering an area of 16.04 square kilometers and 12 Prospecting Licenses covering 98.19 square kilometers located in north-central Tanzania. The company was formerly known as Tanzanian Gold Corporation and changed its name to TRX Gold Corporation in May 2022. TRX Gold Corporation was incorporated in 1990 and is based in Oakville, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
